Contact

All Stories

  1. Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals

    Article • Journal of Hepatology, October 2023, Elsevier

    Dr NAOHIKO MASAKI

  2. Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan

    Article • Scientific Reports, October 2022, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  3. Characteristics of patients aged over 75 years with hepatitis C virus infection treated with direct‐acting antivirals in Japan: Evidence based on the nationwide, real‐world database in Japan

    Article • Hepatology Research, March 2021, Wiley

    Dr NAOHIKO MASAKI

  4. Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals

    Article • Liver Cancer, January 2021, Karger Publishers

    Dr NAOHIKO MASAKI

  5. Nationwide survey on activities of regional core centers for the management of liver disease in Japan: Cumulative analyses by the Hepatitis Information Center 2009–2017

    Article • Hepatology Research, December 2019, Wiley

    Dr NAOHIKO MASAKI

  6. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis

    Article • Journal of Gastroenterology and Hepatology, March 2019, Wiley

    Dr NAOHIKO MASAKI

  7. Medication Adherence Among Patients With Chronic Hepatitis Receiving Antiviral Treatment

    Article • Gastroenterology Nursing, March 2019, Wolters Kluwer Health

    Dr NAOHIKO MASAKI

  8. POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33

    Article • Scientific Reports, January 2019, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  9. Factors improving the utility of antiviral therapy for chronic hepatitis B: A nationwide multicenter study in Japan

    Article • Hepatology Research, August 2018, Wiley

    Dr NAOHIKO MASAKI

  10. Genome-wide association studies identifyPRKCBas a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population

    Article • Human Molecular Genetics, January 2017, Oxford University Press (OUP)

    Dr NAOHIKO MASAKI

  11. Safety Profile of Telaprevir-Based Triple Therapy in Elderly Patients: A Real-World Retrospective Cohort Study

    Article • Biological and Pharmaceutical Bulletin, January 2017, Pharmaceutical Society of Japan

    Kazuki Ide, Dr NAOHIKO MASAKI

  12. Cost-Outcome Description of PEG-IFN-α2b+RBV for Hepatitis C: Results Based on the Interferon Database

    Article • Biological and Pharmaceutical Bulletin, January 2017, Pharmaceutical Society of Japan

    Kazuki Ide, Dr NAOHIKO MASAKI

  13. Risk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C: A Real-World Retrospective Cohort Study

    Article • Biological and Pharmaceutical Bulletin, January 2017, Pharmaceutical Society of Japan

    Kazuki Ide, Dr NAOHIKO MASAKI

  14. The Safety Profile of Telaprevir-Based Triple Therapy in Clinical Practice: A Retrospective Cohort Study

    Article • Biological and Pharmaceutical Bulletin, January 2017, Pharmaceutical Society of Japan

    Kazuki Ide, Dr NAOHIKO MASAKI

  15. Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy

    Article • Cytokine, December 2016, Elsevier

    Dr NAOHIKO MASAKI

  16. Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C

    Article • PLoS ONE, October 2016, PLOS

    Dr NAOHIKO MASAKI

  17. Hepatitis B virus vaccination-related seroprevalence among health-care personnel in a Japanese tertiary medical center

    Article • Hepatology Research, April 2016, Wiley

    Dr NAOHIKO MASAKI

  18. Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study

    Article • Drug Design Development and Therapy, March 2016, Dove Medical Press

    Dr NAOHIKO MASAKI, Kazuki Ide

  19. Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study

    Article • Biological and Pharmaceutical Bulletin, January 2016, Pharmaceutical Society of Japan

    Kazuki Ide, Dr NAOHIKO MASAKI

  20. Regional Differences in Hepatitis C Treatment with Peginterferon and Ribavirin in Japan in Both Genotype 1 and Genotype 2: A Retrospective Cohort Study

    Article • Biological and Pharmaceutical Bulletin, January 2016, Pharmaceutical Society of Japan

    Kazuki Ide, Dr NAOHIKO MASAKI

  21. Usefulness of Magnetic Resonance Imaging for the Diagnosis of Hemochromatosis with Severe Hepatic Steatosis in Nonalcoholic Fatty Liver Disease

    Article • Internal Medicine, January 2016, Japanese Society of Internal Medicine

    Dr NAOHIKO MASAKI

  22. Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan

    Article • Journal of Gastroenterology and Hepatology, December 2015, Wiley

    Dr NAOHIKO MASAKI

  23. Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution

    Article • BMC Gastroenterology, December 2015, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  24. Appropriate use of virtual touch quantification and FibroScan® M and XL probes according to the skin capsular distance

    Article • Journal of Gastroenterology, October 2015, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  25. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey

    Article • Journal of Gastroenterology, October 2015, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  26. The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus

    Article • Journal of Gastroenterology, September 2015, Springer Science + Business Media

    Dr Hidetaka Hamasaki, Akahito Sako, Dr NAOHIKO MASAKI

  27. Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study

    Article • BMC Public Health, June 2015, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  28. Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model

    Article • BMC Gastroenterology, April 2015, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  29. A thymine–adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus

    Article • Journal of Gastroenterology, March 2015, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  30. Nucleoside analogs treatment of chronic hepatitis B in Nepal

    Article • Hepatology Research, February 2015, Wiley

    Dr NAOHIKO MASAKI

  31. Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C

    Article • Human Genetics, December 2014, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  32. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection

    Article • Journal of Gastroenterology, December 2014, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  33. Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C:a retrospective study using the Japanese Interferon Database

    Article • Drug Design Development and Therapy, December 2014, Dove Medical Press

    Dr NAOHIKO MASAKI

  34. Pretreatment prediction of the outcome of response‐guided peginterferon‐α and ribavirin therapy for chronic hepatitis C

    Article • Journal of Gastroenterology and Hepatology, November 2014, Wiley

    Dr NAOHIKO MASAKI

  35. Efficacy and safety of interferon treatment in elderly patients with chronic hepatitis C in Japan: A retrospective study using the Japanese Interferon Database

    Article • Hepatology Research, October 2014, Wiley

    Dr NAOHIKO MASAKI

  36. High-throughput and sensitive next-generation droplet digital PCR assay for the quantitation of the hepatitis C virus mutation at core amino acid 70

    Article • Journal of Virological Methods, October 2014, Elsevier

    Dr NAOHIKO MASAKI

  37. Acute Hepatitis C in HIV-1 Infected Japanese Cohort: Single Center Retrospective Cohort Study

    Article • PLoS ONE, June 2014, PLOS

    Dr NAOHIKO MASAKI

  38. IL28B Polymorphisms and Clinical Implications for Hepatitis C Virus Infection in Uzbekistan

    Article • PLoS ONE, March 2014, PLOS

    Dr NAOHIKO MASAKI

  39. New Susceptibility and Resistance HLA-DP Alleles to HBV-Related Diseases Identified by a Trans-Ethnic Association Study in Asia

    Article • PLoS ONE, February 2014, PLOS

    Dr NAOHIKO MASAKI

  40. Validation of the 3-Day Rule for Stool Bacterial Tests in Japan

    Article • Internal Medicine, January 2014, Japanese Society of Internal Medicine

    Dr NAOHIKO MASAKI, Akahito Sako

  41. 肝炎ウイルス陽性患者に対する診療体制をどうするか

    Article • Nihon Naika Gakkai Zasshi, January 2014, Japanese Society of Internal Medicine

    Dr NAOHIKO MASAKI

  42. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults

    Article • Hepatology, November 2013, Wiley

    Dr NAOHIKO MASAKI

  43. Quantification of collagen and elastic fibers using whole-slide images of liver biopsy specimens

    Article • Pathology International, June 2013, Wiley

    Dr NAOHIKO MASAKI

  44. Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients

    Article • Journal of Gastroenterology, April 2013, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  45. Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype

    Article • Journal of Infection and Chemotherapy, January 2013, Elsevier

    Dr NAOHIKO MASAKI

  46. chronic hepatitis C

    Article • The American Journal of Human Genetics, October 2012, Elsevier

    Dr NAOHIKO MASAKI

  47. Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy

    Article • Journal of Gastroenterology and Hepatology, August 2012, Wiley

    Dr NAOHIKO MASAKI

  48. Factors responsible for the discrepancy betweenIL28Bpolymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients

    Article • Hepatology Research, April 2012, Wiley

    Dr NAOHIKO MASAKI

  49. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study

    Article • Journal of Gastroenterology, October 2011, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  50. Easy-to-use phylogenetic analysis system for hepatitis B virus infection

    Article • Hepatology Research, August 2011, Wiley

    Dr NAOHIKO MASAKI

  51. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma

    Article • Hepatology, June 2011, Wiley

    Dr NAOHIKO MASAKI

  52. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

    Article • Journal of Hepatology, March 2011, Elsevier

    Dr NAOHIKO MASAKI

  53. Acute hepatitis B in Japan: Incidence, clinical practices and health policy

    Article • Hepatology Research, November 2010, Wiley

    Professor Hideo Yasunaga, Dr NAOHIKO MASAKI, Akahito Sako

  54. Erythropoietic Protoporphyria

    Article • Clinical Gastroenterology and Hepatology, August 2010, Elsevier

    Dr NAOHIKO MASAKI

  55. Usefulness of Positron Emission and Computed Tomography Scan in Early Evaluation of Treatment Response in Gastrointestinal Stromal Tumor

    Article • Clinical Gastroenterology and Hepatology, March 2010, Elsevier

    Dr NAOHIKO MASAKI

  56. Dynamic Epidemiology of Acute Viral Hepatitis in Japan

    Article • Intervirology, January 2010, Karger Publishers

    Dr NAOHIKO MASAKI

  57. Multi-center clinical studies for strategies to improve patients' accessibility to peginterferon therapy: Consideration based on both prospective study and retrospective study

    Article • Kanzo, January 2010, Japan Society of Hepatology

    Dr NAOHIKO MASAKI

  58. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

    Article • Nature Genetics, September 2009, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  59. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease

    Article • Journal of Hepatology, September 2009, Elsevier

    Dr NAOHIKO MASAKI

  60. Prediction of Need for Urgent Endoscopy and Treatment Outcomes in Upper GI Bleeding Utilizing Risk Scoring Systems

    Article • Gastrointestinal Endoscopy, April 2009, Elsevier

    Dr NAOHIKO MASAKI

  61. Oxidative stress in hepatocytes and stimulatory state of Kupffer cells after reperfusion differ between warm and cold ischemia in rats

    Article • Liver International, December 2008, Wiley

    Dr NAOHIKO MASAKI

  62. ESDにて摘除し得た大きさ4.5cmの食道悪性黒色腫の1例

    Article • Progress of Digestive Endoscopy, January 2007, Japan Gastrointestinal Endoscopy Society

    Dr NAOHIKO MASAKI

  63. Usefulness of elastometry in evaluating the extents of liver fibrosis in hemophiliacs coinfected with hepatitis C virus and human immunodeficiency virus

    Article • Hepatology Research, June 2006, Elsevier

    Dr NAOHIKO MASAKI

  64. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

    Article • Hepatology, January 2006, Wiley

    Dr NAOHIKO MASAKI

  65. 食道表在癌の質的診断，深達度診断における拡大内視鏡の有用性について

    Article • Progress of Digestive Endoscopy, January 2006, Japan Gastrointestinal Endoscopy Society

    Dr NAOHIKO MASAKI

  66. 本邦に於けるＥ型肝炎ウイルス感染の統計学的・疫学的・ウイルス学的特徴：全国集計２５４例に基づく解析

    Article • Kanzo, January 2006, Japan Society of Hepatology

    Dr NAOHIKO MASAKI

  67. Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon‐α2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia

    Article • Journal of Viral Hepatitis, April 2005, Wiley

    Dr NAOHIKO MASAKI

  68. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis

    Article • Journal of Hepatology, March 2005, Elsevier

    Dr NAOHIKO MASAKI

  69. Usefullness of magnifying endoscopy in diagnosis of early gastric cancer

    Article • Progress of Digestive Endoscopy, January 2005, Japan Gastrointestinal Endoscopy Society

    Dr NAOHIKO MASAKI

  70. Present state of hepatitis E virus epidemiology in Tokyo, Japan

    Article • Hepatology Research, November 2003, Elsevier

    Dr NAOHIKO MASAKI

  71. Article • Digestive Diseases and Sciences, January 2002, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  72. Alpha-Fetoprotein and Highly Active Antiretroviral Therapy in Patients Coinfected with HIV-1 and Hepatitis C Virus

    Article • European Journal of Clinical Microbiology & Infectious Diseases, May 2001, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  73. Large spleno-caval shunt not accompanied by cirrhosis or encephalopathy

    Article • Journal of Gastroenterology, March 1996, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  74. Use of prostaglandin I2 analog in treatment of massive hepatic necrosis associated with endothelial cell injury and diffuse sinusoidal fibrin deposition

    Article • Digestive Diseases and Sciences, January 1995, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  75. Contribution of Hepatitis C Virus Infection to the Development of Sjögren’s Syndrome in Japan

    Article • January 1994, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  76. Marked clinical improvement in patients with hepatocellular carcinoma by surgical removal of extended tumor mass in right atrium and pulmonary arteries

    Article • Cancer Chemotherapy and Pharmacology, January 1994, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  77. Regulating factors of liver regeneration after hepatectomy

    Article • Cancer Chemotherapy and Pharmacology, January 1994, Springer Science + Business Media

    Dr NAOHIKO MASAKI

  78. In situ detection of oxidative stress in rat hepatocytes

    Article • The Journal of Pathology, May 1992, Wiley

    Dr NAOHIKO MASAKI

  79. Usefulness of pulsed doppler ultrasound in detection of angiographically evident recurrence of hepatocellular carcinoma after arterial embolization treatment

    Article • Hepatology, March 1991, Wiley

    Dr NAOHIKO MASAKI

  80. Marked hypophosphatemia with decreased serum 1,25-dihydroxyvitamin D in a patient with hepatocellular carcinoma complicating liver cirrhosis.

    Article • Japanese Journal of Medicine, January 1991, Japanese Society of Internal Medicine

    Dr NAOHIKO MASAKI

  81. Protease inhibitors do not prevent the killing of cultured hepatocytes by cystamine

    Article • Biochemical and Biophysical Research Communications, August 1989, Elsevier

    Dr NAOHIKO MASAKI

  82. Intracellular acidosis protects cultured hepatocytes from the toxic consequences of a loss of mitochondrial energization

    Article • Archives of Biochemistry and Biophysics, July 1989, Elsevier

    Dr NAOHIKO MASAKI

  83. Mitochondrial damage as a mechanism of cell injury in the killing of cultured hepatocytes by tert-butyl hydroperoxide

    Article • Archives of Biochemistry and Biophysics, May 1989, Elsevier

    Dr NAOHIKO MASAKI

  84. tert-Butyl hydroperoxide kills cultured hepatocytes by peroxidizing membrane lipids

    Article • Archives of Biochemistry and Biophysics, March 1989, Elsevier

    Dr NAOHIKO MASAKI

  85. Exchange Blood Transfusion for Acute Hepatic Failure: Its Limited Availability Depending on the Type of Injury in Rats

    Article • Artificial Organs, June 1988, Wiley

    Dr NAOHIKO MASAKI

  86. Enhancement of carbon tetrachloride-induced liver injury by glucagon and insulin treatment

    Article • Research in Experimental Medicine, January 1988, Springer Science + Business Media

    Dr NAOHIKO MASAKI